MEDTRONIC PLC

(MDT)
  Report
Delayed Nyse  -  05/24 04:00:01 pm EDT
105.59 USD   +1.28%
05/23Cowen Lowers Medtronic's Price Target to $125 From $141, Maintains Outperform Rating
MT
05/19Medtronic to announce financial results for its fourth quarter and full fiscal year 2022
PR
05/19Oppenheimer Adjusts Medtronic Price Target to $120 From $125, Maintains Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Medtronic plc Announces Three-Month Results from an On-Label, Prospective, Multi-Center Study Showing Meaningful Pain Relief Using DTM™ SCS Endurance Therapy

01/14/2022 | 12:00pm EDT

Medtronic plc announced three-month results from an on-label, prospective, multi-center study showing meaningful pain relief using DTM™ SCS endurance therapy, a modified, lower-energy variation of the company's Differential Target Multiplexed™ (DTM) Spinal Cord Stimulation (SCS) therapy for chronic overall, back or leg pain. At 3 months, patients treated with DTM SCS endurance therapy reported meaningful pain relief as measured by a 3.9 cm reduction in overall pain on the 10 cm Visual Analog Scale (VAS)2. Patients also reported an average 4.3 cm decrease in back pain, and an average 5.0 cm decrease in leg pain. The Visual Analog Scale (VAS) is a widely used and accepted measure for pain intensity that captures patient-reported pain levels on a scale of 0-10. These 3-month results are consistent with those of a prior feasibility study3 and add to the body of DTM SCS evidence demonstrating that DTM SCS endurance therapy can provide effective pain relief along with additional quality of life and functional benefits for patients. Additional 3-month data include: 69% of patients improved to a less disabled category as measured by the Oswestry Disability Index, with 63% having minimal or moderate disability at 3-months compared to just 16% at baseline; 75% of patients were very satisfied or somewhat satisfied with their therapy at 3-months. Modeling based on actual three-month data also shows that DTM SCS endurance therapy enables between 5.5-7.5 years device longevity when programmed on the Vanta™ recharge-free neurostimulator. For those in need of a rechargeable device, DTM SCS endurance therapy programmed on the Intellis™ rechargeable neurostimulator allows either rapid recharge (5 minutes per day) or recharges of approximately one hour every 12 days.


© S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
MEDTRONIC PLC 1.28% 105.59 Delayed Quote.0.78%
ON SEMICONDUCTOR CORPORATION -2.49% 54.5 Delayed Quote.-17.71%
All news about MEDTRONIC PLC
05/23Cowen Lowers Medtronic's Price Target to $125 From $141, Maintains Outperform Rating
MT
05/19Medtronic to announce financial results for its fourth quarter and full fiscal year 202..
PR
05/19Oppenheimer Adjusts Medtronic Price Target to $120 From $125, Maintains Outperform Rati..
MT
05/19Opsens Presents Results of First-in-human Study of SavvyWire at European Conf
MT
05/17Citigroup Adjusts Medtronic's Price Target to $120 From $127, Reiterates Buy Rating
MT
05/17EUROPCR : Medtronic renal denervation system shows better blood pressure control with sign..
AQ
05/13Medtronic Says FDA Approves Onyx Frontier Drug-Eluting Stent
DJ
05/13Medtronic Receives US FDA Ok for Onyx Frontier Drug-Eluting Coronary Stent System
MT
05/13Medtronic receives FDA approval for latest generation drug-eluting coronary stent syste..
PR
05/13Medtronic Receives FDA Approval for Latest Generation Drug-Eluting Coronary Stent Syste..
CI
More news
Analyst Recommendations on MEDTRONIC PLC
More recommendations
Financials (USD)
Sales 2022 32 051 M - -
Net income 2022 5 743 M - -
Net Debt 2022 20 802 M - -
P/E ratio 2022 26,5x
Yield 2022 2,29%
Capitalization 142 B 142 B -
EV / Sales 2022 5,07x
EV / Sales 2023 4,84x
Nbr of Employees 90 000
Free-Float 99,8%
Chart MEDTRONIC PLC
Duration : Period :
Medtronic plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDTRONIC PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 105,59 $
Average target price 122,23 $
Spread / Average Target 15,8%
EPS Revisions
Managers and Directors
Geoffrey Straub Martha Chairman & Chief Executive Officer
Megan Fulton Riddle Vice President
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Laura Mauri Chief Scientific, Medical & Regulatory Officer
Gregory L. Smith Executive VP-Global Operations & Supply Chain
Sector and Competitors
1st jan.Capi. (M$)
MEDTRONIC PLC0.78%139 869
ABBOTT LABORATORIES-18.27%201 411
BECTON, DICKINSON AND COMPANY4.57%73 262
HOYA CORPORATION-21.65%38 307
BAXTER INTERNATIONAL INC.-14.53%36 944
AMERISOURCEBERGEN CORPORATION13.01%31 985